---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-065416"
form_type: "8-K"
ticker: "PLRX"
cik: "0001746473"
company_name: "PLIANT THERAPEUTICS, INC."
filed_at: "2024-03-12T23:59:59+00:00"
generated_at: "2026-06-04T23:08:16.220021+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Pliant Therapeutics announces accelerated Phase 2b/3 trial for bexotegrast and upsizes debt facility to $150M

## Summary
- BEACON-IPF trial implemented as pivotal, adaptive Phase 2b/3 design after EU and global health authority acceptance; expected to shorten late-stage development.
- Phase 3 enrollment begins immediately after Phase 2b completes; sample size increased by 90 patients to support registration.
- Oxford Finance debt facility upsized to $150M from $100M; initial $30M drawn, additional $70M contingent on bexotegrast milestones.
- Cash and equivalents of $495.7M as of Dec 31, 2023 plus new facility expected to fund operations through 2026.
- Bexotegrast is an oral dual-selective αvβ6/αvβ1 integrin inhibitor for IPF and PSC.

## SEC filing metadata
- accession: 0001193125-24-065416
- form_type: 8-K
- ticker: PLRX
- cik: 0001746473
- company_name: PLIANT THERAPEUTICS, INC.
- filed_at: 2024-03-12T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 2.03, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1746473/000119312524065416/0001193125-24-065416-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1746473/000119312524065416/d759675d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-065416
- JSON: https://secwatch.observer/filing/0001193125-24-065416.json
- Plain text: https://secwatch.observer/filing/0001193125-24-065416.txt

## Key facts
- Debt Financings
  PLIANT THERAPEUTICS, INC. incurred credit facility of $150.0 million with Oxford Finance LLC at (i) the greater of (a) 1-month term SOFR and (b) three and one-half percent (3.5 maturing March 1, 2029, which may be extended to March 1, 2030.
  - Instrument: credit facility
  - Principal: $150.0 million
  - Counterparty: Oxford Finance LLC
  - Rate: (i) the greater of (a) 1-month term SOFR and (b) three and one-half percent (3.5
  - Maturity: March 1, 2029, which may be extended to March 1, 2030
  - Event: incurrence
  source text: pursuant to which, the Lenders have agreed to lend the Company, subject to the terms and conditions therein, a series of term loans up to an aggregate principal amount of $150.0 million (the “Term Loans”), of which $50.0 million is subject to the Lender’s sole discretion. Pursuant to the Agreement, the Company drew an initial Term Loan of $30.0 million on the
  evidence_url: https://www.sec.gov/Archives/edgar/data/1746473/000119312524065416/0001193125-24-065416-index.htm
- Material Agreements
  PLIANT THERAPEUTICS, INC. amended Amended and Restated Loan and Security Agreement with Oxford Finance LLC and the lenders valued at $150.0 million (effective 2024-03-11).
  - Action: amendment
  - Agreement: credit facility
  - Counterparty: Oxford Finance LLC and the lenders
  - Value: $150.0 million
  - Effective: 2024-03-11
  source text: On March 11, 2024 (the “Effective Date”), Pliant Therapeutics, Inc. (the “Company”) entered into an Amended and Restated Loan and Security Agreement (“Agreement”) by and among the Company, the lenders from time to time party thereto (each a “Lender” and collectively, the “Lenders”) and Oxford Finance LLC, in its capacity as collateral agent (in such capacity, the “Agent”), which amends and restates, in its entirety, the Loan and Security Agreement, dated as of May 4, 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/1746473/000119312524065416/0001193125-24-065416-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.